TRBV25OR9-2

Across TCGA pan-cancer cohorts, TRBV25OR9-2 RNA is linked to patient survival in 3 of 34 cancer types, making it the most broadly survival-associated TRBV25OR9-2 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TRBV25OR9-2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRBV25OR9-2 expression acts as an unfavorable survival marker.

BLCA, BRCA, and LIHC are the cancer types where TRBV25OR9-2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.242	0.629	.003	72	view →
BRCA	DFS	Tertile	II,III,IV	0.806	0.943	.002	54	view →
LIHC	DFS	Tertile	All	0.106	0.553	.047	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRBV25OR9-2–BLCA (DFS)

Open the BLCA breakdown →